A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

Patients with aggressive multiple sclerosis (MS) are at increased risk of rapid accrual of disability and disease progression, so early detection is critical The window of opportunity for treating ...